文献速递白血病

热量与营养限制增强急性淋巴细胞白血病化疗疗效:IDEAL试验

Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial.
PubMed 文献 · Blood Adv · 2021-01-01

IDEAL试验纳入40例10–21岁新诊断B-ALL患者,与80例历史对照比较,评估诱导期热量/营养限制联合运动对脂肪增量和MRD的影响。

要点

  • 超重/肥胖B-ALL诱导期热量限制可减少脂肪增加并降低MRD风险。
  • 干预依从性(≥75%饮食)和可行性(≥80%完成访视)均达标。
  • 需前瞻性随机试验验证该干预对化疗疗效的增益作用。

核心结论

  • IDEAL干预可行,在超重/肥胖患者中减少脂肪增加,并降低MRD风险。
  • 这是首个在血液恶性肿瘤中提示饮食/运动热量限制可能增强化疗疗效并改善疾病反应的研究。
  • 需前瞻性随机试验验证。

研究设计与样本

  • IDEAL试验为干预性研究,纳入40例10–21岁新诊断B-ALL患者,与80例近期历史对照比较。
  • 干预设计目标为诱导期热量缺口≥20%、减少脂肪摄入/血糖负荷、增加活动。
  • 终点包括脂肪增量(主要)、MRD≥0.01%、依从性/可行性。
  • 整合生物学探索超重/肥胖生理生物标志物。
  • 试验注册号NCT02708108(IDEAL)和NCT01317940(历史对照)。

主要发现

  • 试验超过依从性(≥75%总体饮食)和可行性(≥80%完成访视)阈值。
  • 整合生物学发现IDEAL干预增加循环脂联素并降低胰岛素抵抗。

关键数值与推荐

  • 诱导期热量缺口目标≥20%。
  • 依从性阈值:≥75%总体饮食。
  • 可行性阈值:≥80%完成访视。
  • MRD阳性阈值:≥0.01%。

临床怎么用

  • 对超重/肥胖B-ALL患者诱导期可考虑饮食/运动热量限制以辅助降低MRD。
  • 实施需监测依从性和可行性,确保热量缺口≥20%并减少脂肪摄入/血糖负荷。
  • 目前证据来自非随机对照试验,应等待前瞻性随机验证后再广泛推荐。

局限性

  • 研究为非随机设计,与历史对照比较,可能存在偏倚。
  • 样本量较小(n=40),需更大规模随机试验验证。
  • 总体脂肪变化未达显著差异,获益仅限于超重/肥胖亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Being overweight or obese (OW/OB) during B-cell acute lymphoblastic leukemia (B-ALL) induction is associated with chemoresistance as quantified by minimal residual disease (MRD). We hypothesized that caloric and nutrient restriction from diet/exercise could lessen gains in fat mass (FM) and reduce postinduction MRD. The Improving Diet and Exercise in ALL (IDEAL) trial enrolled patients 10 to 21 years old, newly diagnosed with B-ALL (n = 40), in comparison with a recent historical control (n = 80). Designed to achieve caloric deficits ≥20% during induction, reduce fat intake/glycemic load, and increase activity, IDEAL's end points were FM gain (primary), MRD ≥0.01%, and adherence/feasibility. Integrated biology explored biomarkers of OW/OB physiology. IDEAL intervention did not significantly reduce median FM change from baseline overall (+5.1% [interquartile range [IQR], 15.8] vs +10.7% [IQR, 16.0]; P = .13), but stratified analysis showed benefit in those OW/OB (+1.5% [IQR, 6.6] vs +9.7% [IQR, 11.1]; P = .02). After accounting for prognostic factors, IDEAL intervention significantly reduced MRD risk (odds ratio, 0.30; 95% confidence interval, 0.09-0.92; P = .02). The trial exceeded its adherence (≥75% of overall diet) and feasibility (≥80% completed visits) thresholds. Integrated biology found the IDEAL intervention increased circulating adiponectin and reduced insulin resistance. The IDEAL intervention was feasible, decreased fat gain in those OW/OB, and reduced MRD. This is the first study in any hematologic malignancy to demonstrate potential benefit from caloric restriction via diet/exercise to augment chemotherapy efficacy and improve disease response. A prospective, randomized trial is warranted for validation. These trials were registered at www.clinicaltrials.gov as #NCT02708108 (IDEAL trial) and #NCT01317940 (historical control).

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Orgel E, Framson C, Buxton R, et al. Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial. Blood Adv. 2021. PMID: 33792627. doi:10.1182/bloodadvances.2020004018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。